Deciphera Pharmaceuticals (DCPH) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a buy rating in a research note issued to investors on Tuesday, October 2nd.

DCPH has been the topic of a number of other reports. JPMorgan Chase & Co. increased their price objective on shares of Deciphera Pharmaceuticals from $30.00 to $33.00 and gave the stock an overweight rating in a research report on Monday, June 4th. Leerink Swann initiated coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, September 24th. They issued an underperform rating and a $28.00 price objective on the stock. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, June 4th. Piper Jaffray Companies increased their price objective on shares of Deciphera Pharmaceuticals to $50.00 and gave the stock an overweight rating in a research report on Tuesday, June 12th. Finally, Raymond James initiated coverage on shares of Deciphera Pharmaceuticals in a research report on Wednesday, August 29th. They issued an outperform rating and a $47.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $48.09.

Shares of NASDAQ DCPH opened at $30.81 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.44 and a current ratio of 18.44. The stock has a market cap of $1.46 billion and a PE ratio of -10.30. Deciphera Pharmaceuticals has a 12-month low of $15.15 and a 12-month high of $45.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.03. As a group, sell-side analysts expect that Deciphera Pharmaceuticals will post -2.61 EPS for the current year.

A number of hedge funds have recently modified their holdings of the business. Orbimed Advisors LLC grew its stake in Deciphera Pharmaceuticals by 30.8% in the 2nd quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock worth $78,924,000 after acquiring an additional 472,800 shares in the last quarter. Redmile Group LLC grew its stake in Deciphera Pharmaceuticals by 79.9% in the 2nd quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock worth $58,123,000 after acquiring an additional 655,800 shares in the last quarter. FMR LLC grew its stake in Deciphera Pharmaceuticals by 33.5% in the 2nd quarter. FMR LLC now owns 1,182,091 shares of the company’s stock worth $46,515,000 after acquiring an additional 296,571 shares in the last quarter. Emerald Advisers Inc. PA grew its stake in Deciphera Pharmaceuticals by 23.0% in the 2nd quarter. Emerald Advisers Inc. PA now owns 592,224 shares of the company’s stock worth $23,304,000 after acquiring an additional 110,785 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Deciphera Pharmaceuticals by 18.2% in the 2nd quarter. BlackRock Inc. now owns 591,064 shares of the company’s stock worth $23,258,000 after acquiring an additional 91,185 shares in the last quarter. Institutional investors and hedge funds own 53.53% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

See Also: NASDAQ Stock Market Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply